PT716611E - Metodo para reduzir a lesao do miocardio durante um enfarte do miocardio agudo - Google Patents

Metodo para reduzir a lesao do miocardio durante um enfarte do miocardio agudo

Info

Publication number
PT716611E
PT716611E PT94929047T PT94929047T PT716611E PT 716611 E PT716611 E PT 716611E PT 94929047 T PT94929047 T PT 94929047T PT 94929047 T PT94929047 T PT 94929047T PT 716611 E PT716611 E PT 716611E
Authority
PT
Portugal
Prior art keywords
esterase inhibitor
pct
myocardial infarction
acute myocardial
acute
Prior art date
Application number
PT94929047T
Other languages
English (en)
Inventor
Willem Theodoor Hermens
Cornelis Erik Hack
Original Assignee
Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanquin Bloedvoorziening filed Critical Sanquin Bloedvoorziening
Publication of PT716611E publication Critical patent/PT716611E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT94929047T 1993-09-01 1994-08-31 Metodo para reduzir a lesao do miocardio durante um enfarte do miocardio agudo PT716611E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93202572 1993-09-01

Publications (1)

Publication Number Publication Date
PT716611E true PT716611E (pt) 2002-06-28

Family

ID=8214075

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94929047T PT716611E (pt) 1993-09-01 1994-08-31 Metodo para reduzir a lesao do miocardio durante um enfarte do miocardio agudo

Country Status (10)

Country Link
US (1) US6090777A (pt)
EP (1) EP0716611B1 (pt)
JP (2) JP4077030B2 (pt)
AT (1) ATE212859T1 (pt)
AU (1) AU678064B2 (pt)
DE (1) DE69429816T2 (pt)
DK (1) DK0716611T3 (pt)
ES (1) ES2171465T3 (pt)
PT (1) PT716611E (pt)
WO (1) WO1995006479A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19829014A1 (de) * 1998-06-30 2000-01-05 Centeon Pharma Gmbh Modifizierter C1-Esterase-Inhibitor zur Blockierung der Infektiosität von HIV
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
CA2426115A1 (en) * 2003-04-18 2004-10-18 Victor Gurewich Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
US20090010916A1 (en) * 2006-06-22 2009-01-08 Victor Gurewich C-1 Inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
PT3028716T (pt) 2006-10-10 2020-11-23 Regenesance B V Inibição do complemento para regeneração nervosa melhorada
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
JP6289511B2 (ja) * 2013-02-28 2018-03-07 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 羊水塞栓の治療剤
AU2014224599B2 (en) 2013-03-08 2018-11-08 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
PT2968434T (pt) 2013-03-15 2017-09-18 Shire Viropharma Inc Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase
WO2014207199A1 (en) * 2013-06-28 2014-12-31 Csl Behring Gmbh Combination therapy using a factor xii inhibitor and a c1-inhibitor
EP3280440B1 (en) 2015-04-06 2022-11-16 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
FR2601034B1 (fr) * 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
WO1991006650A1 (en) * 1989-10-27 1991-05-16 Cetus Corporation C1 inhibitor muteins and uses thereof
WO1992022320A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor

Also Published As

Publication number Publication date
AU7823994A (en) 1995-03-22
ATE212859T1 (de) 2002-02-15
DK0716611T3 (da) 2002-05-21
JP2008056705A (ja) 2008-03-13
JP4077030B2 (ja) 2008-04-16
DE69429816D1 (de) 2002-03-21
US6090777A (en) 2000-07-18
ES2171465T3 (es) 2002-09-16
EP0716611A1 (en) 1996-06-19
EP0716611B1 (en) 2002-02-06
JPH09501946A (ja) 1997-02-25
WO1995006479A1 (en) 1995-03-09
DE69429816T2 (de) 2002-09-19
AU678064B2 (en) 1997-05-15

Similar Documents

Publication Publication Date Title
PT716611E (pt) Metodo para reduzir a lesao do miocardio durante um enfarte do miocardio agudo
NO307027B1 (no) Anvendelse av riluzol ved behandling av neurologiske lesjoner relatert til traumatiske skader
MY129293A (en) The use of mmp-13 selective inhibitors for the treatment of osteoarthristis and other mmp-mediated disorders
EP1007556A4 (en) TROPONIN SUB-UNITS AND FRAGMENTS FOR USE AS INHIBITORS OF ANGIOGENESIS
MX9700237A (es) Combinaciones inhibidoras de proteasa retroviral.
ZA88798B (en) Dental anti-plaque and anti-caries agent
ES2136723T3 (es) Utilizacion de n-aril-metilen-etilen-diamino-triacetatos, n-aril-metilen-imino-diacetatos o n,n'-diaril-metilen-etilen-diamino-acetatos contra el estres oxidante.
HUP0002755A2 (hu) Eljárások szklerózis multiplexben szenvedő betegek kezelésére konszenzus interferonnal
DK0723444T3 (da) Levobupivacain, som er egnet til behandling af kronisk smerte
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
DE69333639D1 (en) Trypsininhibitoren
ATE152628T1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
DK0876158T3 (da) Ny medicinsk anvendelse af en ACE-inhibitor til behandling af mavesurhedssymptomer
CZ157795A3 (en) Pharmaceutical preparations for treating prostatitis
CA2170739A1 (en) Method to reduce myocardial injury during acute myocardial infarction
BG103859A (en) The use of 1-ar(alk)yl-imidazolin-2-on for the treatment of fear and stress conditions
ATE185144T1 (de) Antimessenger oligonukleotide und urokinaserezeptor umkehrung des invasive phänotyps transformieter menschlicher fibroblasten durch antimessenger oligonukleotidinhibierung von urokinaserezeptoren-expression
CO5040221A1 (es) Sal fumarato de (r)-5-(metilaminosulfonilmetil)-3-(n-metil- pilrrolidin-2-ilmetil)-1h-indol, composiciones farmaceuticas que contienen la misma y un procedimiento para preparar di- cha sal
GEP20033130B (en) Inhibitors of IMPDH Enzyme
GEP19991605B (en) Inhibitor, Its Obtaining and Use
MD1783G2 (ro) Metodă de tratament al epilepsiei
UA9672A (uk) Спосіб лікування деструктивних форм гострого панкреатиту